Tidemark’s Alaunos Therapeutics TCRT Stock Holding History

Tidemark’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6	Hold	2	–	–	﹤0.01%	900
2025 Q4	$6	Buy	+2	New	+$6	﹤0.01%	658
2025 Q2	–	Sell	-2	Closed	-$3	–	752
2025 Q1	$3	Buy	+2	New	+$3	﹤0.01%	703
2024 Q4	–	Sell	-2	Closed	-$6	–	679
2024 Q3	$6	Sell	2 -1	-33%	-$4	﹤0.01%	623
2024 Q2	$18	Hold	3	–	–	﹤0.01%	619
2024 Q1	$47	Hold	3	–	–	﹤0.01%	690
2023 Q4	$28	Buy	+3	New	+$36	﹤0.01%	689

Other funds holding TCRT

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tidemark's TCRT Position: Q1 2026 in Review

Tidemark held its Alaunos Therapeutics (TCRT) position steady in Q1 2026 at 2 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #900.

Tidemark first reported a position in TCRT in Q4 2023 and has held it in 7 quarters since. The position peaked at $47 in Q1 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

Tidemark held 2 shares of Alaunos Therapeutics worth $6 as of Q1 2026.
Tidemark left its Alaunos Therapeutics share count unchanged in Q1 2026.
Alaunos Therapeutics made up ﹤0.01% of Tidemark's portfolio in Q1 2026, its #900 holding.
Tidemark first reported a position in Alaunos Therapeutics in Q4 2023 and has held it in 7 quarters since.
Tidemark's Alaunos Therapeutics position peaked at $47 in Q1 2024.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Tidemark's 13F filing for Q1 2026, filed 7 May 2026.